BioSpace News Archive

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn ® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

Immunovia AB (publ) (“Immunovia”), a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer, announced today that Karin Almqvist Liwendahl will join Immunovia as Chief Financial Officer (CFO).

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced upcoming presentations at the American Society of Human Genetics (ASHG) 2021 Meeting, taking place October 18-22, 2021, and at the American Society of Nephrology’s (ASN) Kidney Week 2021.

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences.

On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 2021, Beijing.

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), and Chiesi Global Rare Diseases, today announced the final dosing of the last patient in the phase III BALANCE clinical trial of pegunigalsidase alfa (PRX–102), or the BALANCE Study, for the proposed treatment of Fabry disease.

Shineco, Inc. announced that its ticker symbol on the Nasdaq Stock Market (NASDAQ) will change to “SISI” at the open of market trading on Monday, October 18, 2021.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with BYOMass, Inc. for systems pharmacology modeling in chronic diseases.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that two abstracts on amyotrophic lateral sclerosis (ALS) will be presented during the 146th Annual Meeting of the American Neurological Association (ANA2021), being held virtually October 17-19 .

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at October 1, 2021:.